Clinical trials: Metastatic Solid Tumor Cancer
Metastatic Solid Tumors
Phase I/Ib Multiple Ascending Dose Study in China
The purpose of this study was to evaluate the maximum tolerated dose (MTD) and pharmacokinetics (PK) of Avelumab monotherapy in Chinese subjects.
- Trial name
- NCT03523390
- Testing
- Avelumab 3 mg/kg Q2W, Avelumab 10 mg/kg Q2W, Avelumab 20 mg/kg Q2W
- Where
- 3 sites in China
- Volunteers
- 24 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Neoplasms
BI 6727 (Volasertib) in Combination With Cisplatin or Carboplatin in Patients With Advanced or Metastatic Solid Tumour
The primary objective of this trial is to identify the maximum tolerated dose (MTD) of BI 6727 therapy in terms of drug-related adverse events when combined with a platinum therapy (cisplatin or carboplatin).
- Trial name
- NCT00969761
- Testing
- BI-6727, BI 6727
- Where
- 2 sites in Belgium
- Volunteers
- 61 people
- Sponsor
- Boehringer Ingelheim
Solid Tumor, Hodgkin's Lymphoma
An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies
This is an open-label study of INCB047986 given to two distinct groups of patients (Group 1 and Group 2) with advanced malignancies.
- Conditions
- Solid Tumor, Hodgkin's Lymphoma, NHL (Non-Hodgkin Lymphoma), Pancreatic Cancer
- Trial name
- NCT01929941
- Testing
- INCB047986, Gemcitabine, nab-paclitaxel
- Where
- 3 sites in United States
- Volunteers
- 5 people
- Sponsor
- Incyte Corporation
Neoplasms
Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of Sorafenib and Eribulin in Combination
This Phase 1 study will be conducted in an open-label, non-randomized, dose-escalation design in subjects with advanced, metastatic or refractory solid malignancy who are not candidates for standard therapy.
- Trial name
- NCT01585870
- Testing
- Sorafenib (Nexavar, BAY43-9006), Eribulin
- Where
- 4 sites in France, Germany
- Volunteers
- 40 people
- Sponsor
- Bayer
Unresectable Melanoma, Metastatic Melanoma
A Clinical Study of the Safety and Activity of the Investigational Cell Therapy NEO-PTC-01 in Patients With Advanced Melanoma
This study will investigate the safety and activity of NEO-PTC-01 in patients with unresectable or metastatic melanoma. NEO-PTC-01 is an autologous personalized T cell (PTC) product for adoptive cell therapy that is manufactured…
- Trial name
- NCT04625205
- Testing
- NEO-PTC-01, IL-2, PD-1 Inhibitors
- Where
- 2 sites in Belgium, Netherlands
- Volunteers
- 22 people
- Sponsor
- BioNTech US Inc.
Breast Cancer, Leukemia
Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as doxorubicin hydrochloride liposome, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Breast Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00237627
- Testing
- PS-341, Doxil, Velcade
- Where
- United States
- Volunteers
- 107 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Breast Cancer, Breast Cancer Stage IV
A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer
The purpose of this study to find out whether mirdametinib is a safe treatment for people with advanced solid tumor cancer that has certain mutations.
- Conditions
- Breast Cancer, Breast Cancer Stage IV, HER2-negative Breast Cancer, Solid Carcinoma
- Trial name
- NCT05054374
- Testing
- Mirdametinib, Fulvestrant
- Where
- 4 sites in United States
- Volunteers
- 6 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Cancer, Breast Cancer
A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors
The purpose of this study is to characterize the safety and tolerability of ALTA2618 in adults with AKT1 E17K-mutant advanced solid tumors.
- Conditions
- Cancer, Breast Cancer, Endometrial Cancer, Metastatic Cancer
- Trial name
- NCT06533059
- Testing
- ALTA2618
- Where
- 31 sites in United States, Australia and 6 more
- Volunteers
- 110 people
- Sponsor
- Alterome Therapeutics, Inc.
Advanced Solid Tumor, Metastatic Solid Tumor
A Study to Assess Safety and Efficacy of SOT201 in Patients With Advanced/Metastatic Cancer
This is a Phase 1, open-label, dose escalation study to assess the safety, tolerability, and preliminary efficacy of SOT201 as monotherapy for participants aged 18 years or above with advanced unresectable or metastatic solid…
- Trial name
- NCT06163391
- Testing
- SOT201
- Where
- 6 sites in United States, Belgium and 3 more
- Volunteers
- 40 people
- Sponsor
- SOTIO Biotech AG
Metastatic Solid Cancers, Colorectal Cancer
Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer
Background: Many cancer cells produce substances called antigens that are unique to each cancer. These antigens stimulate the body s immune responses.
- Conditions
- Metastatic Solid Cancers, Colorectal Cancer, Breast Cancer, Non-Small Cell Lung Cancer
- Trial name
- NCT06253520
- Testing
- Aldesleukin, Fludarabine, Cyclophosphamide
- Where
- United States
- Volunteers
- 210 people
- Sponsor
- National Cancer Institute (NCI)
Solid Tumors, Non-small Cell Lung Cancer
Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034)
The purpose of this study is to assess the efficacy and safety of navarixin (MK-7123) in combination with pembrolizumab (MK-3475) in adults with one of three types of solid tumors: Programmed Death-Ligand 1 (PD-L1) positive…
- Conditions
- Solid Tumors, Non-small Cell Lung Cancer, Castration Resistant Prostate Cancer, Microsatellite Stable Colorectal Cancer
- Trial name
- NCT03473925
- Testing
- Navarixin, Pembrolizumab
- Where
- 14 sites in United States, Australia and 3 more
- Volunteers
- 107 people
- Sponsor
- Merck Sharp & Dohme LLC
Locally Advanced or Metastatic Solid Tumors
First-In-Human (FIH) Study of W0180 as Single Agent and in Combination With Pembrolizumab in Adults With Locally Advanced or Metastatic Solid Tumors
The purpose of this study will be to determine the Maximum Tolerated Dose (MTD) and describe dose-limiting toxicities (DLTs) of W0180 given as monotherapy and in combination with pembrolizumab (anti-PD-1).
- Trial name
- NCT04564417
- Testing
- W0180, Pembrolizumab
- Where
- 5 sites in France, Spain
- Volunteers
- 33 people
- Sponsor
- Pierre Fabre Medicament
Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
Testing the Sequential Combination of the Anti-cancer Drugs Olaparib Followed by Adavosertib (AZD1775) in Patients With Advanced Solid Tumors With Selected Mutations and PARP Resistance, STAR Study
This phase I trial studies the side effects and best dose of adavosertib when given together with olaparib in treating patients with solid tumors that have spread to other places in the body (advanced) with selected mutations.
- Conditions
- Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
- Trial name
- NCT04197713
- Testing
- Adavosertib, Olaparib
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- National Cancer Institute (NCI)
Solid Tumor
Safety, Pharmacokinetics, and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab (BGB-A317) in Participants With Advanced Solid Tumors
This study will evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of BGB-B167 monotherapy and in combination with tislelizumab (BGB-A317) in participants with select advanced solid…
- Trial name
- NCT05494762
- Testing
- BGB-B167, Tislelizumab
- Where
- 8 sites in United States, Australia
- Volunteers
- 55 people
- Sponsor
- BeiGene
Metastatic Cancer, Solid Tumor
Sym022 (Anti-LAG-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas
This is the first study to test Sym022 in humans. The primary purpose of this study is to see if Sym022 is safe and tolerable for patients with locally advanced/unresectable or metastatic solid tumor malignancies or lymphomas…
- Conditions
- Metastatic Cancer, Solid Tumor, Lymphoma
- Trial name
- NCT03489369
- Testing
- Sym022
- Where
- 3 sites in United States, Canada
- Volunteers
- 15 people
- Sponsor
- Symphogen A/S
Oncology, Chemotherapeutic Toxicity
EMR Chemotoxicity Risk Calculator To Decrease Chemotherapy Toxicity
This study will formally test the quality improvement intervention of an EMR based tool that informs medical oncologists visiting a patient for the first time of potential risk of chemotherapy toxicity.
- Conditions
- Oncology, Chemotherapeutic Toxicity, Metastatic Solid Tumor
- Trial name
- NCT05809557
- Testing
- Chemotherapy toxicity tool, Oncology Consultation
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Gastric Cancer, Esophageal Cancer
Study of Epirubicin (Pharmorubicin®), Carboplatin (Paraplatin®) and Capecitabine (Xeloda®) (ECC) in the Treatment of Unresectable Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer With Pharmacogenetic Correlates
Although declining in incidence, gastric/gastroesophageal cancer is still a commonly diagnosed malignancy in Canada. Patients who have undergone surgical resection for early disease have a high rate of local recurrence and…
- Conditions
- Gastric Cancer, Esophageal Cancer, Tumors
- Trial name
- NCT00130936
- Testing
- Epirubicin, Carboplatin, Capecitabine
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- AHS Cancer Control Alberta
Locally Advanced or Metastatic Solid Tumors
A Study of RO7821657 in Participants With Solid Tumors
The aim of this study is to characterize the safety and tolerability of RO7821657, describe its pharmacokinetics (PK), and evaluate pharmacodynamic and biomarker effects to support selection of the recommended Phase 2 dose(s)…
- Trial name
- NCT07883577
- Testing
- RO7821657
- Volunteers
- 405 people
- Sponsor
- Hoffmann-La Roche
Metastatic Solid Tumor, Colorectal Cancer
Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors
This open-label, phase Ib/II study of surufatinib in combination with tislelizumab will evaluate the safety, tolerability, PK and efficacy in patients with advanced solid tumors.
- Conditions
- Metastatic Solid Tumor, Colorectal Cancer, Neuroendocrine Tumors, Small Cell Lung Cancer
- Trial name
- NCT04579757
- Testing
- Surufatinib and Tislelizumab _ Part 1, Surufatinib and Tislelizumab _ Part 2
- Where
- 18 sites in United States
- Volunteers
- 87 people
- Sponsor
- Hutchmed
Neoplasms
A Study of BI 853520 in Japanese and Taiwanese Patients With Various Types of Advanced or Metastatic Cancer
The primary objective of this trial is to explore the safety and tolerability of BI 853520 monotherapy and determine the maximum tolerated dose (MTD) for Japanese and Taiwanese patients with advanced or metastatic solid tumours.
- Trial name
- NCT01905111
- Testing
- BI 853520
- Where
- 2 sites in Japan, Taiwan
- Volunteers
- 21 people
- Sponsor
- Boehringer Ingelheim